FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2041633812> ?p ?o ?g. }

• W2041633812 endingPage "443" @default.
• W2041633812 startingPage "437" @default.
• W2041633812 abstract "OBJECTIVES: Several probiotic compounds have shown promise in the therapy of ulcerative colitis (UC). However, a strong sustained benefit remains to be seen. Uncontrolled pilot studies suggest that a probiotic preparation (VSL#3) maintains remission in mild to moderate UC and reduces active inflammation in adult patients. Aims of our prospective, 1-year, placebo-controlled, double-blind study were to assess the efficacy of VSL#3 on induction and maintenance of remission and to evaluate the safety and tolerability of the probiotic preparation therapy in children with active UC. METHODS: A total of 29 consecutive patients (mean age: 9.8 years; range: 1.7-16.1 years; female/male: 13/16) with newly diagnosed UC were randomized to receive either VSL#3 (weight-based dose, range: 450-1,800 billion bacteria/day;n=14) or an identical placebo (n=15) in conjunction with concomitant steroid induction and mesalamine maintenance treatment. Children were prospectively evaluated at four time points: within 1 month, 2 months, 6 months, and 1 year after diagnosis or at the time of relapse. Lichtiger colitis activity index and a physician's global assessment were used to measure disease activity. At baseline, within 6 months and 12 months or at the time of relapse, all patients were assessed endoscopically and histologically. RESULTS: All 29 patients responded to the inflammatory bowel disease (IBD) induction therapy. Remission was achieved in 13 patients (92.8%) treated with VSL#3 and IBD therapy and in 4 patients (36.4%) treated with placebo and IBD therapy (P<0.001). Overall, 3 of 14 (21.4%) patients treated with VSL#3 and IBD therapy and 11 of 15 (73.3%) patients treated with placebo and IBD therapy relapsed within 1 year of follow-up (P=0.014; RR= 0.32; CI=0.025-0.773; NNT=2). All 3 patients treated with VSL#3 and 6 of 11 (54.5%) patients treated with placebo relapsed within 6 months of diagnosis. At 6 months, 12 months, or at time of relapse, endoscopic and histological scores were significantly lower in the VSL#3 group than in the placebo group (P<0.05). There were no biochemical or clinical adverse events related to VSL#3. CONCLUSIONS: This is the first pediatric, randomized, placebo-controlled trial that suggests the efficacy and safety of a highly concentrated mixture of probiotic bacterial strains (VSL#3) in active UC and demonstrates its role in maintenance of remission. Am J Gastroenterol 2009; 104:437-443; doi:10.1038/ajg.2008.118; published online 20 January 2009" @default.
• W2041633812 created "2016-06-24" @default.
• W2041633812 creator A5002010208 @default.
• W2041633812 creator A5016693591 @default.
• W2041633812 creator A5023154420 @default.
• W2041633812 creator A5055256352 @default.
• W2041633812 creator A5091255858 @default.
• W2041633812 creator A5091718554 @default.
• W2041633812 date "2009-01-20" @default.
• W2041633812 modified "2023-10-10" @default.
• W2041633812 title "Effect of a Probiotic Preparation (VSL#3) on Induction and Maintenance of Remission in Children With Ulcerative Colitis" @default.
• W2041633812 cites W1691455568 @default.
• W2041633812 cites W1974941155 @default.
• W2041633812 cites W1987064800 @default.
• W2041633812 cites W1987811803 @default.
• W2041633812 cites W1987925515 @default.
• W2041633812 cites W1990397098 @default.
• W2041633812 cites W1992108310 @default.
• W2041633812 cites W2004989915 @default.
• W2041633812 cites W2010372358 @default.
• W2041633812 cites W2010713573 @default.
• W2041633812 cites W2011756150 @default.
• W2041633812 cites W2013188093 @default.
• W2041633812 cites W2014818191 @default.
• W2041633812 cites W2018091449 @default.
• W2041633812 cites W2021174967 @default.
• W2041633812 cites W2032040196 @default.
• W2041633812 cites W2040821545 @default.
• W2041633812 cites W2043545267 @default.
• W2041633812 cites W2046776539 @default.
• W2041633812 cites W2076837393 @default.
• W2041633812 cites W2090210288 @default.
• W2041633812 cites W2091250795 @default.
• W2041633812 cites W2096380782 @default.
• W2041633812 cites W2105270270 @default.
• W2041633812 cites W2114164427 @default.
• W2041633812 cites W2114424280 @default.
• W2041633812 cites W2124334818 @default.
• W2041633812 cites W2131691027 @default.
• W2041633812 cites W2132731835 @default.
• W2041633812 cites W2139387284 @default.
• W2041633812 cites W2139759128 @default.
• W2041633812 cites W2145051098 @default.
• W2041633812 cites W2153551892 @default.
• W2041633812 cites W2158820172 @default.
• W2041633812 cites W4292994528 @default.
• W2041633812 doi "https://doi.org/10.1038/ajg.2008.118" @default.
• W2041633812 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19174792" @default.
• W2041633812 hasPublicationYear "2009" @default.
• W2041633812 type Work @default.
• W2041633812 sameAs 2041633812 @default.
• W2041633812 citedByCount "443" @default.
• W2041633812 countsByYear W20416338122012 @default.
• W2041633812 countsByYear W20416338122013 @default.
• W2041633812 countsByYear W20416338122014 @default.
• W2041633812 countsByYear W20416338122015 @default.
• W2041633812 countsByYear W20416338122016 @default.
• W2041633812 countsByYear W20416338122017 @default.
• W2041633812 countsByYear W20416338122018 @default.
• W2041633812 countsByYear W20416338122019 @default.
• W2041633812 countsByYear W20416338122020 @default.
• W2041633812 countsByYear W20416338122021 @default.
• W2041633812 countsByYear W20416338122022 @default.
• W2041633812 countsByYear W20416338122023 @default.
• W2041633812 crossrefType "journal-article" @default.
• W2041633812 hasAuthorship W2041633812A5002010208 @default.
• W2041633812 hasAuthorship W2041633812A5016693591 @default.
• W2041633812 hasAuthorship W2041633812A5023154420 @default.
• W2041633812 hasAuthorship W2041633812A5055256352 @default.
• W2041633812 hasAuthorship W2041633812A5091255858 @default.
• W2041633812 hasAuthorship W2041633812A5091718554 @default.
• W2041633812 hasConcept C126322002 @default.
• W2041633812 hasConcept C141071460 @default.
• W2041633812 hasConcept C142724271 @default.
• W2041633812 hasConcept C168563851 @default.
• W2041633812 hasConcept C197934379 @default.
• W2041633812 hasConcept C204787440 @default.
• W2041633812 hasConcept C27081682 @default.
• W2041633812 hasConcept C2775862500 @default.
• W2041633812 hasConcept C2776694085 @default.
• W2041633812 hasConcept C2778260677 @default.
• W2041633812 hasConcept C2778283404 @default.
• W2041633812 hasConcept C2778375690 @default.
• W2041633812 hasConcept C2779134260 @default.
• W2041633812 hasConcept C2779384505 @default.
• W2041633812 hasConcept C2780255968 @default.
• W2041633812 hasConcept C2780479503 @default.
• W2041633812 hasConcept C523546767 @default.
• W2041633812 hasConcept C54355233 @default.
• W2041633812 hasConcept C71924100 @default.
• W2041633812 hasConcept C86803240 @default.
• W2041633812 hasConcept C90924648 @default.
• W2041633812 hasConceptScore W2041633812C126322002 @default.
• W2041633812 hasConceptScore W2041633812C141071460 @default.
• W2041633812 hasConceptScore W2041633812C142724271 @default.
• W2041633812 hasConceptScore W2041633812C168563851 @default.
• W2041633812 hasConceptScore W2041633812C197934379 @default.
• W2041633812 hasConceptScore W2041633812C204787440 @default.

• next